

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON THE PHARMACEUTICAL MARKET IN THE REPUBLIC OF KAZAKHSTAN

Kabdoldanova A.B., Pichhadze G.M., Shopabaeva A.R., Khimenko S.V.

Kazakh National Medical University named S.D. Asfendiyarov, Almaty,
The Republic of Kazakhstan

National University of Pharmacy, Kharkiv, Ukraine

kabdoldanova@bk.ru

Non-steroidal anti-inflammatory drugs (NSAID) are widely used in modern clinical practice. More than 30 million people use NSAIDs annually worldwide. The reasons behind high usage of NSAIDs are the following: the wide range of their pharmacotherapeutic applications; their anti-inflammatory, analgesic and antipyretic effects; their effectiveness in treatment of various diseases.

Our goal is the general estimation of assortment and quality of NSAIDs on the pharmaceutical market of the Republic of Kazakhstan (RK).

We conducted quantitative and qualitative market studies of the size, share and segmentation of the NSAIDs market.

The studies show that NSAIDs are represented by 85 trade names at the pharmaceutical market of the RK, most of them are foreign products. The share of locally produced is only 1.16% of all registered in the RK drugs. The main exporters of NSAIDs are: India (which exports 18 trade names to the RK market and its share is 21%); Germany and The Russian Federation - 9 trade names (11%); the RK - 8 trade names (9%); Japan - 6 trade names (7%); Belarus - 5 trade names (6%). Other producers come from Great Britain, Italy, Turkey, Estonia, Bulgaria, Ireland, Spain, Poland, Romania, France, Armenia, Egypt, USA, Thailand, Switzerland, Hungary; and they export 4 or less trade names, with a market share of approximately 1-4% each. The analysis of available NSAID dosage types shows that gels occupy the leading position - 38%; the share of capsules, ointments, pills and plasters is around 7-11% total. The share of injections, eye drops, granules, trans-dermal systems and other drug forms makes 1-4% of the market.

Thus, the small market share of local NSAIDs (1.16%) in the assortment of drugs of this group and their high usage in treating the most common diseases in the RK indicates the necessity for local pharmaceutical companies to produce them.